NEW YORK (GenomeWeb News) – Goldman Sachs today downgraded Life Technologies and Affymetrix while it upgraded Myriad Genetics and Qiagen.

In a research note, analyst Isaac Ro made revisions to several life science tools and genomics-related firms to favor those "with high exposure to the US and strong [free cash flow] where capital allocation can improve." Changes were made also to reflect rising pressure in the European Union, continuing headwinds to the National Institutes of Health, and slower growth in China.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.